Expertise in
2
conditions

Emilio Usala

Via Jenner, 
Cagliari, IT 
Expertise in
2
conditions
Via Jenner, 
Cagliari, IT 

Overview

Emilio Usala practices practicing medicine in Cagliari, Italy.

Mr. Usala is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Leukemia, Trichorhinophalangeal Syndrome Type 1 (TRPS1), Schinzel-Giedion Syndrome, and Splenectomy.

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Via Jenner, Cagliari, 09124, Italy
Other Locations
Catanzaro, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Enrollment Status: Completed
Publish Date: April 18, 2025
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
Mid to Long-term Quality of Life Effects Of imatiNIb Versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS)
Mid to Long-term Quality of Life Effects Of imatiNIb Versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS)
Enrollment Status: Unknown
Publish Date: August 06, 2018
Intervention Type: Other
View 2 Less Clinical Trials

14 Total Publications

Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy.
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy.
Journal: Annals of hematology
Published: June 14, 2021

Frequently Asked Questions about Emilio Usala

Is Emilio Usala a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Emilio Usala is classified as an Distinguished expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Emilio Usala participate in research or clinical trials?

Yes. Emilio Usala has published 14 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Emilio Usala's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Usala's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile